Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of VLA1601 Zika Vaccine
NCT03425149Phase 1Completed
- Sponsor
- Valneva
- Start
- Feb 2018
- Primary completion
- Jun 2018
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VLA1601 in Zika virus infection (5 arms), sponsored by Valneva. Primary endpoint: Rate of subjects with solicited adverse events including injection site and systemic reactions at 7 days. Started Feb 2018; status: completed.
02
Drugs
VLA1601
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT03425149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03425149.